BBNX — Beta Bionics, Inc. stock price, charts and financials

QT66Beta Bionics, Inc.

Beta Bionics, Inc. (NASDAQ: BBNX) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
21.43
-0.75-3.38%
OverviewShort InterestFilings
BBNXQT66Beta Bionics, Inc.·NASDAQ
21.43-3.38%
Filing
Down 3.4% — Filed an 8-K material-event report (2026-09-17) — details in the filing.
Medium confidence
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
CBLL+2.04%$25.00ENOV-4.61%$17.80IRMD+0.19%$82.74BVS-4.32%$12.63PRCT+0.15%$19.47INMD-0.27%$14.54AVR+0.60%$8.42AORT-4.56%$23.88
Snapshot
Index-P/E-EPS (ttm)-1.68Insider Own12.50%Shs Outstand44.99MPerf Week29.17%
Market Cap964.13MForward P/E-EPS next Y-2.29Insider Trans-3.23%Shs Float20.04MPerf Month12.67%
Enterprise Value789.13MPEG-EPS next Q-0.55Inst Own-Short Float46.92%Perf Quarter62.47%
Income-72.00MP/S8.10EPS this Y-26.26%Inst Trans-Short Ratio8.09Perf Half Y101.60%
Sales119.00MP/B3.77EPS next Y-8.17%ROA-24.96%Short Interest9.40MPerf YTD-29.67%
Book/sh5.69P/C5.36EPS next 5Y-ROE-26.30%52W High32.71 -34.48%Perf Year-7.99%
Cash/sh4.00P/FCF-EPS past 3/5Y-ROIC-30.98%52W Low8.80 143.52%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin58.31%Volatility13.38% 7.73%Perf 5Y-
Dividend TTM-EV/Sales6.63EPS Y/Y TTM-31.25%Oper. Margin-69.75%ATR (14)1.59Perf 10Y-
Dividend Ex-Date-Quick Ratio7.96Sales Y/Y TTM83.08%Profit Margin-61.32%RSI (14)63.22Recom2.25
Dividend Gr. 3/5Y-Current Ratio8.88EPS Q/Q-35.90%SMA2011.77%Beta1.23Target Price22.00
Payout0.00%Debt/Eq0.02Sales Q/Q39.13%SMA5022.46%Rel Volume2.40Prev Close22.18
Employees422LT Debt/Eq0.02EarningsOct 27SMA20031.56%Avg Volume1.29MPrice21.43
IPO DateJan 30, 2025Option/ShortYes / YesEPS/Sales Surpr.8.78% 1.75%Net Debt/EBITDA0.53Volume3,090,275Change-3.38%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-15-26ReiteratedRobert W. Baird$14 → $16
Sep-15-26ReiteratedUBS$22 → $25
Sep-15-26ReiteratedTruist SecuritiesBuy$22 → $23
Sep-14-26ReiteratedLeerink PartnersOutperform$27
Jul-28-26ResumedUBSBuy$24 → $22
Jul-15-26ReiteratedGoldman SachsBuy$17 → $19
Jul-13-26ReiteratedTruist SecuritiesBuy$25 → $22
May-27-26ReiteratedGoldman SachsBuy$25 → $17
Feb-18-26ReiteratedLake StreetBuy$40 → $20
Feb-18-26ReiteratedRobert W. Baird$28 → $14
Latest News· Times ET
Sep-17-26
Sep-17-2602:40PM
Beta Bionics (BBNX) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before November 3, 2026 Lead Plaintiff Deadlineprnewswire.com
12:05PM
Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stockglobenewswire.com
11:45AM
Kaplan Fox Alerts Investors of Beta Bionics, Inc. (BBNX) with Significant Losses to a Securities Class Action Deadline on November 3, 2026newsfilecorp.com
10:25AM
Deadline Alert: Beta Bionics, Inc. (BBNX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuitglobenewswire.com
09:06AM
Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pumpzacks.com
07:28AM
Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc. - BBNXglobenewswire.com
06:09AM
BBNX Shareholder Alert: Beta Bionics, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallStprnewswire.com
06:00AM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BBNXprnewswire.com
05:23AM
Faruqi & Faruqi, LLP Urges Beta Bionics (BBNX) Investors to Seek Counsel Before November 3, 2026 Lead Plaintiff Deadline in the Securities Class Actionnewsfilecorp.com
04:24AM
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Beta Bionics, Inc. (BBNX)globenewswire.com
04:00AM
Beta Bionics: Mint Clearance Marks The Shift Toward A Multi-Engine Growth Storyseekingalpha.com
03:26AM
Beta Bionics, Inc. (BBNX) Surges 15.3%: Is This an Indication of Further Gains?zacks.com
Sep-16-26
Sep-16-2602:00PM
BBNX INVESTORS: Contact Kirby McInerney LLP About the Securities Fraud Lawsuit Filed on Behalf of Beta Bionics, Inc. Shareholdersglobenewswire.com
12:32PM
Beta Bionics (NASDAQ: BBNX) Faces Securities Class Action Amid iLet FDA Compliance -- HBSSglobenewswire.com
11:30AM
Kaplan Fox Alerts Beta Bionics, Inc. (BBNX) Investors Who Suffered Losses to a Securities Class Action - Deadline is November 3, 2026newsfilecorp.com
Company

Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue11910065——
Cost of Goods Sold Incl. D&A494529——
Gross Profit695636——
Selling, General and Administrative Excl. Other1139255——
Research and Development383526——
Other Operating Expense
100——
Operating Income-83-72-45——
Interest Expense
000——
Unusual Expense
—————
Non-Operating Income (Expense)10-2-10——
Net Income Before Taxes-72-73-55——
Income Taxes
000——
Consolidated Net Income-72-73-55——
Net Income From Continuing Operations-72-73-55——
Net Income-72-73-55——
EPS (Recurring)-1.68-1.81-1.28——
EPS (Basic, Before Extraordinaries)-1.68-1.81-1.28——
EPS (Diluted)-1.68-1.81-1.28——
EBITDA-72-70-54——
Other After Tax Adjustments
—————
Stock Option Compensation Expense
—————
Price To Earnings Ratio
—————
Price To Sales Ratio8.1012.49———
Gross Margin57.9856.0055.38——
Operating Margin-69.75-72.00-69.23——
Net Margin-60.50-73.00-84.62——
Shares Outstanding454143——
Market Capitalization9641,249———
Operating Lease Expense
—————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$35.46$27.94$20.42$12.91$5.39● Close Price0.00M0.55M1.10M1.65M2.20MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Hopman MarkChief Commercial OfficerSep 16 '26Sale20.1330,779619,64056,479Sep 17
Mensinger MikeChief Product OfficerSep 16 '26Sale22.002,65058,300177,390Sep 17
Hopman MarkChief Commercial OfficerSep 14 '26Sale15.5277512,02886,382Sep 15
Hopman MarkChief Commercial OfficerSep 09 '26Sale18.4636,870680,72387,157Sep 10
Saint SeanPresident & CEOSep 03 '26Sale20.085,641113,259398,429Sep 04
Hopman MarkChief Commercial OfficerSep 02 '26Sale19.115,327101,815124,027Sep 03
Russell Steven JonChief Medical OfficerSep 02 '26Sale19.114,22180,676169,628Sep 03
Mensinger MikeChief Product OfficerSep 02 '26Sale19.114,37583,620180,040Sep 03
Feider StephenChief Financial OfficerSep 02 '26Sale19.116,675127,580159,378Sep 03
Saint SeanPresident & CEOSep 02 '26Sale19.1116,867322,381404,070Sep 03
Feider StephenChief Financial OfficerJun 29 '26Option Exercise5.109,79249,940170,949Jul 02
Feider StephenChief Financial OfficerJun 29 '26Sale17.039,792166,762165,931Jul 02
Feider StephenChief Financial OfficerJun 26 '26Sale17.0510,208174,012165,931Jul 02
Feider StephenChief Financial OfficerJun 26 '26Option Exercise5.1010,08651,438171,157Jul 02
Hopman MarkChief Commercial OfficerJun 24 '26Sale15.011,25818,880129,354Jun 25
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.